Investor Overview

Corporate Profile

Proteon Therapeutics is working to deliver a new future for patients and families affected by kidney and vascular diseases, where innovation drives health improvement and healthcare professionals have the tools they need to improve patient outcomes. Proteon is a late-stage biopharmaceutical company developing potentially transformative treatment options to address some of the most urgent needs in chronic kidney disease (CKD) and peripheral artery disease (PAD) with the goal of redefining how these diseases are treated. More >>
PRTO (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.1 (4.35%)
Data as of 02/23/18 3:59 p.m. ET
Refresh quote